JNJ•benzinga•
This Johnson & Johnson Analyst Turns Bullish On Shifting Focus From Stelara Concerns To Innovative Medicine
Summary
Goldman Sachs upgraded Johnson & Johnson (JNJ) from Neutral to Buy, citing underappreciated Innovative Medicine business and upcoming product cycles.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 9, 2025 by benzinga